Applied Biosystems SOLiD 3 System

描述（由申请人提供）：目前的提案要求资金购买ABI SOLiD V3测序仪，下一代和大规模并行测序平台。下一代仪器的超高通量，加上大大降低的测序成本，使这些成为查询基因组序列和功能的首选平台。大规模平行测序特别适用于表观基因组学和功能基因组学研究，包括染色质结构、组蛋白修饰和变体、调控因子定位; DNA甲基化;转录;以及基因组修饰的定量，例如逆转录病毒载体整合的定位。通过2碱基编码，SOLiD V3系统能够生成高度准确的序列数据，每次运行从来自两个载玻片的> 4亿个可映射读数中输出>20千兆碱基的可映射数据。这个输出大约是目前市场上其他短读段测序仪的两倍，并且，预计到2010年初读段长度将达到100个碱基，原始序列输出将再次翻倍。对下一代测序能力的需求正在经历爆炸式增长，因为越来越多的研究人员意识到该技术的潜力，以影响和加速他们的研究。新仪器将部署在一个完善的、自我支持的核心设施中，该设施已经提供了大量以表观基因组学为重点的下一代测序服务和相关的生物信息学支持，因此非常适合快速转化SOLiD V3的潜力，以满足特定研究项目以及一般研究社区的需求。 公共卫生相关性：目前的提案要求拨款购买ABI SOLiD v3大规模并行测序平台。新仪器将部署在现有核心设施的背景下，并将满足表观基因组和功能基因组测序应用的大量需求，包括染色质结构，调控因子和DNA甲基化的映射和分析。该仪器还将通过提供一个平台来映射模型和患者细胞中治疗载体整合的基因组位点，从而支持基因治疗计划。

DESCRIPTION (provided by applicant): The current proposal requests funds for the purchase of an ABI SOLiD V3 sequencer, a next- generation, and massively parallel sequencing platform. The ultra-high throughput of next- generation instruments, coupled with substantially reduced sequencing costs have made these the platforms of choice for interrogating genome sequence and function. Massively parallel sequencing is particularly well-suited for epigenomic and functional genomics studies, including chromatin structure, histone modifications and variants, regulatory factor localization; DNA methylation; transcription; and quantification of genome modifications such as localization of retroviral vector integrations. With 2-base encoding, the SOLiD V3 system is capable of generating highly accurate sequence data, with an output of >20 gigabases of mappable data per run, from >400 million mappable reads from the two slides with each run of the instrument. This output is roughly double that of other short read sequencers currently on the market, and, with read lengths expected to reach 100 bases by early 2010, the raw sequence output will double again. Demand for next-generation sequencing capacity is experiencing explosive growth as more investigators realize the potential of the technology to impact and accelerate their research. The new instrument will be deployed in the context of a well-established, self- supporting core facility that already provides substantial epigenomics-focused next-generation sequencing services and associated bioinformatics support, and is therefore ideally positioned to rapidly translate the SOLiD V3's potential to meet the needs of specific investigator projects as well as those of the general research community. PUBLIC HEALTH RELEVANCE: The current proposal requests funding to purchase an ABI SOLiD v3 massively parallel sequencing platform. The new instrument will be deployed in the context of an existing core facility, and will address substantial demand for epigenomic and functional genomics sequencing applications including mapping and analysis of chromatin structure, regulatory factors, and DNA methylation. The instrument will also support gene therapy programs by providing a platform to map genomic sites of therapeutic vector integration in model and patient cells.